Burning Rock Biotech (BNR) Operating Expenses (2019 - 2026)

Burning Rock Biotech's Operating Expenses history runs 8 years deep, the most recent figure standing at -$14.0 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 9.5% year-over-year to -$14.0 million; the TTM figure through Mar 2026 stood at -$62.7 million (up 27.1% YoY), while the FY2025 annual figure was -$8.5 million, up 82.25% from the prior year.
• Operating Expenses for Q1 2026 stood at -$14.0 million, up from -$15.8 million in the prior quarter.
• The five-year high for Operating Expenses was -$14.0 million in Q1 2026, with the low at -$55.3 million in Q1 2022.
• The 5-year median for Operating Expenses is -$29.3 million (2024), against an average of -$30.9 million.
• The sharpest annual moves came in 2022 and 2024: Operating Expenses sank 45.57% in 2022, then jumped 48.77% in 2024.
• Burning Rock Biotech's Operating Expenses stood at -$46.2 million in 2022, then rose by 25.49% to -$34.4 million in 2023, then jumped by 31.82% to -$23.5 million in 2024, then soared by 32.63% to -$15.8 million in 2025, then increased by 11.22% to -$14.0 million in 2026.
• Business Quant data shows BNR's Operating Expenses at -$14.0 million in Q1 2026, -$15.8 million in Q4 2025, and -$16.2 million in Q3 2025.